RESUMEN
BACKGROUND: Drug-induced photosensitivity refers to the development of cutaneous adverse events due to interaction between a pharmaceutical compound and sunlight. Although photosensitivity is a very commonly listed side-effect of systemic drugs, reliable data on its actual incidence are lacking so far. OBJECTIVES: A possible approach to evaluate the real-life extent of drug-induced photosensitivity would be an analysis of the frequency of exposure to a given photosensitizing drug combined with an indicator of its photosensitizing potential. This could serve as a basis for developing a pharmaceutical 'heatmap' of photosensitivity. METHODS: The present study investigated the number of reimbursed dispensed packages of potentially photosensitizing drugs in Germany (DE) and Austria (AT) between 2010 and 2017 based on nationwide health insurance-based databases. In addition, an indicator for the photosensitizing potential was established for each drug based on the number of reports on photosensitivity in the literature. RESULTS: This analysis includes means of 632 826 944 (+/-14 894 918) drug dispensings per year in DE and 113 270 754 (+/-1 964 690) in AT. Out of these, the mean percentage of drugs that enlist photosensitivity as a potential side-effect was 49.5% (±0.7) in DE and 48.2% (±1.2) in AT. When plotting the number of reimbursed dispensed packages vs. the number of reports on photosensitivity, two categories of drugs show high numbers for both parameters, that is diuretics and non-steroidal anti-inflammatory drugs (NSAIDs). CONCLUSIONS: Diuretics and NSAIDs appear to be responsible for the greatest part of exposure to photosensitizing drugs with potential implication on public health.
Asunto(s)
Prescripciones de Medicamentos/estadística & datos numéricos , Trastornos por Fotosensibilidad/inducido químicamente , Trastornos por Fotosensibilidad/epidemiología , Fármacos Fotosensibilizantes/efectos adversos , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/farmacología , Austria , Correlación de Datos , Diuréticos/efectos adversos , Diuréticos/farmacología , Interacciones Farmacológicas , Alemania , Humanos , Fármacos Fotosensibilizantes/farmacología , Edición/estadística & datos numéricosRESUMEN
The objective of this study was to explore the electrically assisted transdermal delivery of buprenorphine. Oral delivery of buprenorphine, a synthetic opiate analgesic, is less efficient due to low absorption and large first-pass metabolism. While transdermal delivery of buprenorphine is expected to avoid the first-pass effect and thereby be more bioavailable, use of electrical enhancement techniques (iontophoresis and/or electroporation) could provide better programmability. Another use of buprenorphine is for opiate addiction therapy. However, a patch type device is subject to potential abuse as it could be removed by the addict. This abuse can be prevented if drug particles are embedded in the skin. The feasibility of doing so was investigated by electro-incorporation. Buprenorphine HCl (1 mg/ml) in citrate buffer (pH 4.0) was delivered in vitro across human epidermis via iontophoresis using a current density of 0.5 mA/cm(2) and silver-silver chloride electrodes. Electroporation pulses were also applied in some experiments. For electro-incorporation, drug microspheres or particles were driven into full thickness human skin by electroporation. It was observed that the passive transdermal flux of buprenorphine HCl was significantly enhanced by iontophoresis under anodic polarity. The effectiveness of electro-incorporation seemed inconclusive, with pressure also playing a potential role. Delivery was observed with electro-incorporation, but the results were statistically not different from the corresponding controls.
Asunto(s)
Analgésicos Opioides/administración & dosificación , Buprenorfina/administración & dosificación , Electroporación , Iontoforesis , Piel/metabolismo , Administración Cutánea , Animales , Transporte Biológico , Buprenorfina/farmacocinética , Humanos , PorcinosRESUMEN
Electrically enhanced transdermal delivery of salmon calcitonin could be useful for chronic treatment of postmenopausal osteoporosis and other clinical indications as a superior alternative to parenteral delivery. Calcitonin (50 microg/ml) formulation was prepared in citrate buffer (pH 4.0). Epidermis separated from human cadaver skin was used. Most iontophoresis studies were done at a current density of 0.5 m A cm2. Silver/silver-chloride electrodes were used and calcitonin was found to be best delivered under the anode. The relationship between calcitonin flux and current density during iontophoresis was linear. Passive flux was zero. Flux increased with increasing concentration up to 250 microg/ml but then it levels off. Thus, transdermal delivery of salmon calcitonin may be accomplished to achieve therapeutic levels.
Asunto(s)
Calcitonina/administración & dosificación , Administración Cutánea , Calcitonina/química , Calcitonina/farmacocinética , Química Farmacéutica , Electrodos , Epidermis/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Iontoforesis , Focalización Isoeléctrica , Absorción CutáneaRESUMEN
Electroporation, a standard laboratory method of introducing exogenous molecules into cells, has been gaining importance as a very effective non-viral physical technique of gene delivery. In this study, we have used subcutaneous model of the C6 rat glioma cells and established an optimal condition to obtain very high gene expression in tumor tissues using both reporter and functional genes. Tumors grown on the flanks of Wistar rats are exposed and directly injected with plasmid DNA having the constructs of luciferase, green fluorescent protein and, the fragment of the diphtheria toxin, DT-A. The tumors are then subjected to square wave pulses from an electroporator. Gene expression is found to be several orders of magnitude higher when the tumors are pulsed with the optimized electrical parameters compared to the controls. For luciferase, the enhancement is approximately 135-fold, for the green fluorescent protein, gene expression is seen over a wide area within the sections examined, as contrast to a few punctate dots in the control specimens, and finally, DT-A shows massive death in the tumor tissue. A special circular array of six needles through which pulses are delivered with rotating electric field is found to be highly efficient in transferring genes inside the tumor. Direct injection of plasmid DNA followed by electroporation allows very high in vivo gene transfer and its subsequent expression into tumor tissues. This method may be applicable to any solid tumor.
Asunto(s)
Neoplasias Encefálicas/terapia , Electroporación/métodos , Técnicas de Transferencia de Gen , Terapia Genética , Glioma/terapia , Animales , Toxina Diftérica/genética , Expresión Génica , Marcadores Genéticos , Proteínas Fluorescentes Verdes , Luciferasas/genética , Proteínas Luminiscentes/genética , Plásmidos , Ratas , Ratas WistarRESUMEN
Electrically-assisted delivery by iontophoresis and/or electroporation was used in vitro to deliver the calcium regulating hormones, salmon calcitonin (sCT) and parathyroid hormone (1-34) (PTH) through human epidermis. Such delivery could be useful for chronic treatment of post-menopausal osteoporosis and other clinical indications as a superior alternative to parenteral delivery. sCT (50 microg/ml) or PTH (1-34) (100 microg/ml) formulation was prepared in citrate buffer (pH 4.0 or 5.0, respectively). Epidermis separated from human cadaver skin was used. Iontophoresis was applied using a constant current power source and electroporation with an exponential pulse generator. Silver/silver chloride electrodes were used. A combination of electroporation and iontophoresis resulted in higher transdermal permeation than either one technique alone. Electroporation also shortened the lag time of iontophoretic transdermal delivery of salmon calcitonin. Pulsing at lower voltages followed by iontophoresis did not result in increased transport (over iontophoresis alone), perhaps because the transdermal voltage was very low. The transdermal transport of salmon calcitonin by pulsing with 15 pulses (1 ppm) of 500 V (200 ms) followed by iontophoresis led to a quick input and high flux. The average transdermal voltage was only about 50 V for a 500 V study.
Asunto(s)
Calcitonina/administración & dosificación , Electroporación , Iontoforesis/métodos , Hormona Paratiroidea/administración & dosificación , Fragmentos de Péptidos/administración & dosificación , Administración Cutánea , Calcitonina/uso terapéutico , Sistemas de Liberación de Medicamentos , Epidermis/metabolismo , Femenino , Humanos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Hormona Paratiroidea/uso terapéutico , Fragmentos de Péptidos/uso terapéuticoRESUMEN
We report successful electro-gene therapy (EGT) by using plasmid DNA for tumor-bearing mice. Subcutaneously inoculated CT26 tumor was subjected to EGT, which consists of intratumoral injection of a naked plasmid encoding a marker gene or a therapeutic gene, followed by in vivo electroporation (EP). When this treatment modality is carried out with the plasmid DNA for the green fluorescent protein gene, followed by in vivo EP with the optimized pulse parameters, numerous intensely bright green fluorescent signals appeared within the tumor. EGT, by using the "A" fragment of the diphtheria toxin gene significantly inhibited the growth of tumors, by about 30%, on the flank of mice. With the herpes simplex virus thymidine kinase gene, followed by systemic injection of ganciclovir, EGT was far more effective in retarding tumor growth, varying between 50% and 90%, compared with the other controls. Based on these results, it appears that EGT can be used successfully for treating murine solid tumors.
Asunto(s)
Electroporación/métodos , Terapia Genética/métodos , Plásmidos/uso terapéutico , Simplexvirus/enzimología , Timidina Quinasa/genética , Animales , Antivirales/farmacología , División Celular/genética , Trasplante de Células , Neoplasias del Colon , Toxina Diftérica/genética , Modelos Animales de Enfermedad , Ganciclovir/farmacología , Marcadores Genéticos , Proteínas Fluorescentes Verdes , Histocitoquímica , Proteínas Luminiscentes/genética , Masculino , Ratones , Ratones Endogámicos BALB C , Plásmidos/genética , Simplexvirus/genética , Células Tumorales CultivadasRESUMEN
Electroporation (EP) of drugs and genes into cells in vitro became a standard procedure in molecular biology laboratories in the last decade. Numerous protocols aid the researcher in selecting appropriate procedures; commercial instrumentation is readily available and discussed (1). The more recent transition to applying EP to living tissue poses a new set of requirements and few practical guidelines are available.
RESUMEN
Cancer of the pancreas is currently the fifth leading cause of cancer related deaths with a five year survival of less than 1% In the United States (1). It is one of the most difficult cancers to treat, since it is hard to detect in the early stages. The patients remain asymptomatic until late in the course of the disease. An excellent review of pancreatic carcinoma has appeared (2). Despite the progress made in our understanding of the biology of this cancer (3), the final outcome for this disease has remained extremely poor. Conventional chemotherapeutic agents have not been very effective for human pancreatic adenocarcinoma (4). Use of intratumoral chemotherapy in combination with monoclonal antibodies have been reported to produce better response rate and also reduced toxicity (5,6). Smith and colleagues (7) have recently shown that an injectable gel with a sustained release profile can inhibit tumor growth in vivo in human pancreatic cancer xenografts. This was demonstrated in nude mice with BxPC-3 xenografts using fluorouracil, cisplatin, and doxorubicin with a consequent size reduction of the tumors between 72% and 79%, compared to the controls at day 28 after the first treatment. Although these figures are impressive, by any standard, no cure was reported.
RESUMEN
Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser, a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire tumor mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (> or = 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects.
Asunto(s)
Antimetabolitos Antineoplásicos/administración & dosificación , Bleomicina/administración & dosificación , Carcinoma de Células Escamosas/tratamiento farmacológico , Electroporación/instrumentación , Electroporación/métodos , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Animales , Biopsia , Carcinoma de Células Escamosas/patología , Evaluación Preclínica de Medicamentos , Femenino , Neoplasias de Cabeza y Cuello/patología , Humanos , Imagen por Resonancia Magnética , Masculino , Ratones , Persona de Mediana Edad , Inducción de Remisión , Resultado del TratamientoRESUMEN
It is now medically recognized that sagging skin and other signs of degenerative skin conditions, such as wrinkles and age spots, are caused primarily by oxy-radical damage. Vitamin C (Vit. C), in the form of L-ascorbic acid (Asc), is the one vitamin that can accelerate wound healing, protect fatty tissues from oxidation damage, and play an integral role in collagen synthesis. It is known that the lipid-rich stratum corneum (SC) is a highly resistant barrier to chemical agents penetrating into the skin. This report describes the first feasibility study of electroporation-mediated topical delivery (EMTD) of Asc for potential cosmetic applications. Both a cream formulation (20% Asc) and a crystal suspension (33% Asc) were applied respectively to human cadaver skin and fresh surgical skin. Six exponential pulses at 60 or 100 V and pulse lengths of 2.7-30 ms were selected. EMTD was more effective on fresh human skin than on human cadaver skin. For both skin models, EMTD with cream resulted in a greater enhancement of Vit. C penetration than with suspension. The distribution of electrical fields through the SC, epidermis, and dermis is demonstrated in computer simulation. Assuming that this fresh skin model and certain experimental conditions simulate projected in vivo applications, EMTD of Vit. C may represent an alternative method to ameliorate skin aging.
Asunto(s)
Ácido Ascórbico/administración & dosificación , Cosméticos , Electroporación , Administración Tópica , Ácido Ascórbico/análisis , Cromatografía Líquida de Alta Presión , Simulación por Computador , Electroquímica , Humanos , Modelos Biológicos , Piel/químicaRESUMEN
The curative effects of some chemotherapeutic drugs are impeded by their poor permeation through the cell membrane. This limitation can be overcome by a novel approach called electroporation therapy (EPT), electrochemotherapy (ECT), or electrical impulse chemotherapy (EIC). The method involves application of brief electrical pulses, which destabilize the cell membrane barrier, allowing intracellular access of chemotherapeutic drugs that otherwise would not be able to penetrate the cell membrane effectively. EPT makes it possible to lower the drug dose, thereby relieving the patient of adverse side effects associated with conventional chemotherapy. Even with the lower drug dose, EPT has shown significantly higher efficacy than has conventional chemotherapy. The method is currently being evaluated clinically for treating various cancer indications using the anticancer drugs bleomycin or cisplatin. This article provides a historical perspective and current insights into this new modality of cancer treatment, including basic physical, biological, and medical facts about EPT; computer-assisted development of electrical pulse generators and electrodes necessary to create effective electrical fields in the treatment area; results of cancer cell and tumor treatments in vitro, in animals, and in humans; safety aspects of EPT; potential combined delivery of chemotherapeutic drugs and biological agents to reduce or eliminate metastatic disease; and intracellular delivery of DNA by electroporation for cancer gene therapy.
Asunto(s)
Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Electroporación , Neoplasias/tratamiento farmacológico , Animales , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/uso terapéutico , Bleomicina/administración & dosificación , Bleomicina/uso terapéutico , Ensayos Clínicos como Asunto , HumanosRESUMEN
Bioassay-guided fractionation of the CH2Cl2-MeOH extract of Pinus flexilis using an assay for protein kinase C (PKC) inhibitory activity led to the isolation of the two new bioactive diarylheptanoids (3R)-1,7-bis(3, 4-dihydroxyphenyl)-3-(beta-D-glucopyranosyl)heptan-3-ol (1) and its aglycon (3R)-1,7-bis(3,4-dihydroxyphenyl)heptan-3-ol (2), together with the three known bioactive compounds, hirsutenone (3), oregonin (4), and hirsutanonol (5). The IC50 values of compounds 1-5 in the PKC assay were 1.4, 1.6, 1.4, 8.6, and 4.6 microg/mL, respectively.
Asunto(s)
Diarilheptanoides , Inhibidores Enzimáticos/aislamiento & purificación , Glucosa/análogos & derivados , Heptanol/análogos & derivados , Isoenzimas/antagonistas & inhibidores , Plantas Medicinales/química , Proteína Quinasa C/antagonistas & inhibidores , Dicroismo Circular , Inhibidores Enzimáticos/farmacología , Glucosa/aislamiento & purificación , Glucosa/farmacología , Heptanol/aislamiento & purificación , Heptanol/farmacología , Humanos , Espectroscopía de Resonancia Magnética , Proteína Quinasa C-alfa , Espectrofotometría Infrarroja , Espectrofotometría UltravioletaRESUMEN
In a continuation of our search for potential tumor inhibitors from plants, it was found that the CH2Cl2-MeOH (1:1) extracts from Digitalis purpurea and Penstemon linarioides both showed PKCalpha-inhibitory bioactivity. Bioassay-directed fractionation of the extract from D. purpurea yielded the new, weakly active phenylethanoid glycoside 2-(3-hydroxy-4-methoxy-phenyl)-ethyl-O-(alpha-L-rhamnosyl)-(1-->3) -O- (alpha-L-rhamnosyl)-(1-->6)-4-O-E-feruloyl-beta-D-glucopy ran oside (1) together with the four known compounds calceolarioside A (2), calceolarioside B (3), forsythiaside (4), and plantainoside D (5). The extract from P. linarioides yielded the three known glycosides leucosceptoside A (6), acteoside (7), and poliumoside (8), together with the iridoid plantarenaloside (9). All of the isolated compounds, except compound 9, showed inhibitory activity against PKCalpha with IC50 values (in microM) of 125 (1), 0.6 (2), 4.6 (3), 1.9 (4), 14.8 (5), 19.0 (6), 9.3 (7), and 24.4 (8).
Asunto(s)
Ácidos Cafeicos/aislamiento & purificación , Digitalis/química , Inhibidores Enzimáticos/aislamiento & purificación , Glicósidos/aislamiento & purificación , Isoenzimas/antagonistas & inhibidores , Plantas Medicinales/química , Plantas Tóxicas , Proteína Quinasa C/antagonistas & inhibidores , Ácidos Cafeicos/farmacología , Inhibidores Enzimáticos/farmacología , Glicósidos/farmacología , Humanos , Espectroscopía de Resonancia Magnética , Proteína Quinasa C-alfa , Espectrometría de Masa Bombardeada por Átomos Veloces , Espectrofotometría Infrarroja , Espectrofotometría UltravioletaRESUMEN
Current methods of local drug delivery frequently fail to achieve a prolonged therapeutically effective tissue drug level without producing vascular trauma. A novel double-balloon catheter system, incorporating electroporation technology, has been designed and tested to deliver heparin into rabbit carotid arteries in an overstretch balloon injury model in vivo. Following arterial injury, fluoresceinated heparin was delivered into the volume between the two inflated balloons, and the artery was subjected to an electrical pulse. Catheter deployment and endovascular electrical pulsing were well-tolerated in all animals (N = 21) without adverse hemodynamic and histological changes. Periodic arterial blood samples revealed no abnormalities in the clotting profile or any gross morphological changes in the blood cells up to 8 hr after treatment. Much stronger heparin fluorescence was detected throughout the vessel layers for at least 12 hr in the pulsed samples compared to the control. Histochemical staining of the tissue showed intracellular localization of heparin. Endovascular electroporation may provide better retention and higher therapeutic efficacy than can be achieved by conventional systemic delivery of heparin at clinically safe concentrations.
Asunto(s)
Anticoagulantes/administración & dosificación , Cateterismo Periférico/instrumentación , Sistemas de Liberación de Medicamentos/instrumentación , Electroporación , Heparina/administración & dosificación , Animales , Anticoagulantes/farmacocinética , Presión Sanguínea , Arteria Carótida Común/efectos de los fármacos , Arteria Carótida Común/metabolismo , Arteria Carótida Común/patología , Estenosis Carotídea/tratamiento farmacológico , Estenosis Carotídea/metabolismo , Estenosis Carotídea/patología , Modelos Animales de Enfermedad , Femenino , Heparina/farmacocinética , Inyecciones Intraarteriales , Masculino , Conejos , Seguridad , Resultado del TratamientoRESUMEN
BACKGROUND: A new method of cancer treatment called electroporation therapy (EPT) which uses pulsed electric fields in combination with a chemotherapeutic agent is being developed to treat human pancreatic tumors. Such a combination has been found to increase the cytotoxic effect of the drug to tumor cells. METHODS: Human pancreatic tumors (Pan-4-JCK) were implanted subcutaneously onto nude mice. The animals were treated with EPT using bleomycin, mitomycin C or carboplatin as a single agent, and their effect on tumor growth was monitored over a period of 89 days. RESULTS: The tumors treated with either the drug or pulse alone showed increased tumor growth. However, tumors treated with EPT using any one of the three drugs showed significant to complete regression of tumors. Among the three drugs used, the order of efficacy was: bleomycin >> mitomycin C > carboplatin. CONCLUSIONS: These results are sufficient to warrant limited clinical trials of EPT for pancreatic cancers.
Asunto(s)
Antineoplásicos/administración & dosificación , Bleomicina/administración & dosificación , Carboplatino/administración & dosificación , Electroporación , Mitomicina/administración & dosificación , Neoplasias Pancreáticas/tratamiento farmacológico , Animales , Antineoplásicos/uso terapéutico , Bleomicina/uso terapéutico , Carboplatino/uso terapéutico , División Celular/efectos de los fármacos , Humanos , Ratones , Ratones Desnudos , Mitomicina/uso terapéutico , Neoplasias Pancreáticas/patología , Factores de Tiempo , Trasplante Heterólogo , Células Tumorales CultivadasRESUMEN
BACKGROUND: Electroporation therapy (EPT) uses reversible membrane permeabilization of cells by electrical pulses for intracellular delivery of poorly permeating drugs like bleomycin. This treatment modality has been found to significantly increase the cytotoxic effect of the drug to tumor cells. METHODS: Tumors of human epidermoid carcinoma of larynx (HEp-2) were xenografted subcutaneously in nude mice. EPT consisted of intratumoral injection of belomycin followed by 6 x 100 microseconds square wave electrical pulses of 1130 Volts. The effect of treatment on tumor growth was monitored over a period of 67 days. RESULTS: Complete regression of the tumors was observed in 83% of the treated mice 67 days after treatment. These findings were confirmed by histopathological analysis of tumor samples from the treated sites, which showed complete absence of tumor cells. CONCLUSIONS: The results indicate that electroporation therapy is very effective and has potential for treating laryngeal tumors clinically.
Asunto(s)
Antineoplásicos/administración & dosificación , Electroporación , Neoplasias Laríngeas/terapia , Animales , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Trasplante de NeoplasiasRESUMEN
Bioactivity-directed fractionation of the MeCOEt extract of Trichilia emetica (Meliaceae) resulted in the isolation of the limonoids nymania 1 (1), drageana 4 (3), trichilin A (4), rohituka 3 (5), and Tr-B (7) and the novel seco-A protolimonoid 8. Of these, nymania 1 and Tr-B showed selective inhibitory activity toward DNA repair-deficient yeast mutants. The isolation, structure elucidation, 13C NMR spectral assignments, and biological activities of these compounds are reported.
Asunto(s)
Reparación del ADN/genética , Noresteroides/toxicidad , Plantas Medicinales/química , Saccharomyces cerevisiae/genética , Triterpenos/toxicidad , Secuencia de Carbohidratos , Etiopía , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Datos de Secuencia Molecular , Extractos Vegetales/farmacología , Saccharomyces cerevisiae/efectos de los fármacos , Espectrometría de Masa Bombardeada por Átomos VelocesRESUMEN
Endothelin-1 (ET-1), a peptide isolated from the culture medium of endothelial cells, mediates a variety of physiological and pathological responses including mitogenesis. We have compared the expression of ET receptors in untransformed versus ras-transformed NIH-3T3 murine fibroblasts and in untransformed versus SV40-transformed W138 (VA13) human fibroblasts by ligand binding and Northern analysis. NIH-3T3 and W138 cells displayed high affinity (200 and 220 pM) and high density (23,000 sites/cell and 14,000 sites/cell for NIH-3T3 and W138 cells, respectively) ET receptors. Competition binding experiments using subtype-selective ligands identified these receptors as the ETA subtype. Addition of ET-1 to the cells produced a concentration-dependent increase in intracellular calcium release. Both ras-transformed NIH-3T3 cells and SV40-transformed W138 cells (VA13) completely lacked [125I]ET-1 binding and failed to release calcium when exposed to ET-1. Northern analysis of the polyadenylated RNA (polyA RNA) isolated from untransformed and transformed cells revealed that the steady-state level of ETA receptor RNA was 90-95% less in transformed cells compared to untransformed cells. Thus, the loss of ET receptors as well as the receptor-mediated responses in transformed cells can be explained by down-regulation of ET receptor mRNA.
Asunto(s)
Línea Celular Transformada/metabolismo , Endotelina-1/metabolismo , Fibroblastos/metabolismo , ARN Mensajero/metabolismo , Receptores de Endotelina/metabolismo , Células 3T3 , Animales , Unión Competitiva , Northern Blotting , Calcio/metabolismo , Regulación hacia Abajo , Genes ras/genética , Humanos , Ratones , Virus 40 de los Simios/genéticaRESUMEN
Members of three classes of pyridinylimidazoles bind with varying affinities to CSBP (p38) kinase which is a member of a stress-induced signal transduction pathway. Based upon SAR and protein homology modeling, the pharmacophore and three potential modes of binding to the enzyme are presented. For a subset of pyridinylimidazoles, binding is shown to correlate with inhibition of CSBP kinase activity, whereas no significant inhibition of PKA, PKC alpha and ERK kinase activity is observed.
Asunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/antagonistas & inhibidores , Citocinas/biosíntesis , Inhibidores Enzimáticos/farmacología , Imidazoles/farmacología , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Estrés Fisiológico/metabolismo , Línea Celular , Proteínas Quinasas Dependientes de AMP Cíclico/antagonistas & inhibidores , Humanos , Imidazoles/química , Isoenzimas/antagonistas & inhibidores , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Proteína Quinasa 3 Activada por Mitógenos , Modelos Moleculares , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C-alfa , Relación Estructura-Actividad , Proteínas Quinasas p38 Activadas por MitógenosRESUMEN
Electroporation therapy (EPT), also known as electrochemo-therapy (ECT), of a poorly differentiated human pancreatic carcinoma (Panc-3) implanted subcutaneously in nude mice significantly enhanced the cytotoxicity of bleomycin to tumor cells. A single treatment of intratumoral injection of bleomycin followed by 6 × 99 µs square wave electrical pulses of 1370 V resulted in complete tumor regression in 68% and partial regression (>80%) in 20% of the treated mice on day 28 following treatment. No palpable tumor was observed in 64% of the mice even 120 days after treatment. Histological studies of tissue samples taken from tumor sites 120 days after treatment in the D+E+ group showed complete absence of tumor cells.